Natalia Restrepo

Dr. Natalia Restrepo

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 August 2023 in Antibiotics
Verified
Journal Article
Open access
PDF file
NRNatalia Restrepo
Natalia Restrepo
JBJuan Carlos García Betancur
Juan Carlos García Betancur
CPChristian Jose Pallares
Christian Jose Pallares
MVMaría Virginia Villegas
María Virginia Villegas
Antimicrobial resistance is one of the major global health threats. Antimicrobial stewardship (AMS) has been set as a priority within international action plans to combat this issue. The region of Latin America and the Caribbean are recognized for their high antimicrobial resistance rates; nevertheless, a low number of studies describing implemented interventions for this topic have been published. This review aims to provide an overview of the status of AMS in our region, focusing on the main progress achieved and describing the different published efforts made by countries towards the implementation of antimicrobial stewardship programs (ASP). Common areas of intervention included were (a) education approaches, (b) antimicrobial guideline implementation and monitoring, (c) diagnostic stewardship, (d) technological tools: electronic clinical decision support systems in AMS, (e) pharmacy-driven protocols and collaborative practice agreements, and (f) economic impact. The search demonstrated the varied interventions implemented in diverse healthcare settings; the results accentuate their influence on antimicrobial consumption, antimicrobial resistance, clinical outcomes, and direct economic impact. The integration of multiple strategies within each hospital was highlighted as an essential key to ASP success. Even though the literature found demonstrated clear progress, there is still a special need for strengthening leadership from the top down, defining goals based on needs, and gaining support through policy and financing in LAC.

4 June 2024 in Microbiology Spectrum
Verified
Journal Article
Open access
ECElsa De La Cadena
Elsa De La Cadena
MMMaria Mojica
Maria Mojica
LRLaura J. Rojas
Laura J. Rojas
BCBetsy E. Castro
Betsy E. Castro
JGJuan Carlos García-Betancur
Juan Carlos García-Betancur
MVMaría Virginia Villegas
María Virginia Villegas
Resistance to ceftazidime-avibactam (CZA) due to Klebsiella pneumoniae carbapenemase (KPC) variants is increasing worldwide. We characterized two CZA-resistant clinical Klebsiella pneumoniae strains by antimicrobial susceptibility test, conjugation assays, and WGS. Isolates belonged to ST258 and ST45, and produced a KPC-31 and a novel variant KPC-197, respectively. The novel KPC variant presents a deletion of two amino acids on the Ω-loop (del_168–169_EL) and an insertion of two amino acids in position 274 (Ins_274_DS). Continued surveillance of KPC variants conferring CZA resistance in Colombia is warranted. IMPORTANCE: Latin America and the Caribbean is an endemic region for carbapenemases. Increasingly high rates of Klebsiella pneumoniae carbapenemase (KPC) have established ceftazidime-avibactam (CZA) as an essential antimicrobial for the treatment of infections due to MDR Gram-negative pathogens. Although other countries in the region have reported the emergence of CZA-resistant KPC variants, this is the first description of such enzymes in Colombia. This finding warrants active surveillance, as dissemination of these variants could have devastating public health consequences.

11 November 2024 in Antimicrobial Stewardship & Healthcare Epidemiology
Verified
Journal Article
Open access
PDF file
NRNatalia Restrepo
Natalia Restrepo
JBJuan Carlos García Betancur
Juan Carlos García Betancur
CPChristian José Pallares
Christian José Pallares
LAL’eMir Wassim El Ayoubi
L’eMir Wassim El Ayoubi
PKPattarachai Kiratisin
Pattarachai Kiratisin
MVMaría Virginia Villegas
María Virginia Villegas
Antimicrobial resistance (AMR) is positioning as one of the most relevant threats to global public health and threatens the effective treatment of an ever-growing number of bacterial infections in various healthcare settings, particularly in acute care and surgical units, as well as in the community. Among multidrug-resistant (MDR) gram-negative bacteria (MDRGNB), Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii require special attention, since they account for most of the mortality associated with bacterial infections and are often MDR. It is clear that there is an important global variation in antibiotic resistance profiles among MDRGNB species. Extended-spectrum β-lactamase-producing Enterobacterales, carbapenem-resistant Enterobacterales, DTR-P. aeruginosa, and MDR-A. baumannii are the focus of this review. Here, we summarize a series of relevant studies on risk factors associated with colonization and infection with these MDRGNB. Likewise, we offer a comparative overview of those studies providing scoring systems to predict the risk of infection with these MDR pathogens, and their pros and cons. Despite the variable accuracy of published risk factors for predicting colonization or infection with MDRGNB, these scores are valuable tools that may help anticipate colonization and infection among those colonized. More importantly, they may help reduce unnecessary use of broad-spectrum antimicrobials and guiding the selection of an optimal treatment.

4 November 2025 in Microbiology Spectrum
Verified
Journal Article
Open access
BCBetsy E. Castro
Betsy E. Castro
ECElsa De La Cadena
Elsa De La Cadena
JEJanneth J. Escobar-Arcos
Janneth J. Escobar-Arcos
JBJuan Carlos García Betancur
Juan Carlos García Betancur
NRNatalia Restrepo
Natalia Restrepo
MVMaría Virginia Villegas
María Virginia Villegas
Ceftazidime/avibactam (CZA) is a promising treatment option for infections caused by carbapenem-resistant Enterobacterales (CRE). However, CZA resistance is increasingly reported worldwide, largely due to the emergence of KPC variants and increase of metallo-β-lactamases (MBL). This study describes the mechanisms associated with CZA resistance in circulating Enterobacterales isolates from Colombia, highlighting the challenge this represents for microbiological identification. Between 2021 and 2024, 68 CZA-resistant Enterobacterales isolates were identified by automated methods in seven Colombian cities. Resistance to CZA was subsequently confirmed by broth microdilution and E-test. Carbapenemase production was evaluated using phenotypic tests, such as the mCIM test, Carba NP, lateral flow assay, and qPCR ( bla KPC , bla NDM , bla VIM , bla IMP , and bla OXA-48 ). Whole-genome sequencing was performed on 15 isolates that tested negative for MBL genes. Whole-genome sequencing of these 15 isolates revealed a variety of resistance determinants: six isolates harbored bla KPC-31 , one bla KPC-33 , one bla KPC-8 , five harbored bla PAC-2 , and two co-harbored bla PAC-2 and bla KPC-2 . Notably, bla PAC-2 was located on an IncQ plasmid. However, some of these variants were not detected by phenotypic assays, likely due to their low or undetectable carbapenemase activity. CZA resistance in non-MBL producing Enterobacterales in Colombia is primarily mediated by the presence of bla KPC-31 and emergence of bla PAC-2 . These resistance mechanisms pose significant diagnostic, therapeutic, and epidemiological challenges, as they frequently go undetected by conventional microbiological methods. In this context, enhanced molecular surveillance and improved diagnostic strategies are urgently needed to enable early detection, guide antimicrobial therapy, and support infection control and stewardship efforts. IMPORTANCE: Antibiotic resistance is a serious global health threat. Ceftazidime/avibactam (CZA) is a key treatment option for multidrug-resistant (MDR) Enterobacterales often used when other antibiotics fail. However, bacteria are now developing resistance to this drug as well, making infections increasingly difficult to treat. In this study, we examined CZA-resistant bacteria from multiple cities in Colombia and found uncommon resistance genes across several bacterial species. These genes are frequently missed, as they often do not test positive due to the limitations of most routinely used laboratory tests. Importantly, some of these genes can be transferred between bacteria, increasing the likelihood of indiscriminate dissemination in the hospital setting. Therefore, our findings highlight the urgent need for improved diagnostic tools and molecular surveillance. Early detection will help physicians select effective treatments quickly and prevent the wider dissemination of these MDR-resistant bacteria.

12 December 2025 in Value in Health Regional Issues
Verified
Journal Article
Open access
NRNatalia Restrepo
Natalia Restrepo
ELElkin V. Lemos-Luengas
Elkin V. Lemos-Luengas
JGJuan Carlos García-Betancur
Juan Carlos García-Betancur
WCWanda Cornistein
Wanda Cornistein
DBDiogo Boldim-Ferreira
Diogo Boldim-Ferreira
VMVanessa Moreno
Vanessa Moreno
This study presents a pilot cost analysis and case-study comparison of adherence to antimicrobial stewardship (AMS) guidelines across 6 high-complexity healthcare institutions in Latin America and the Caribbean. It aims to evaluate the economic impact of adhering to these guidelines in hospitals implementing step-by-step processes to establish AMS programs within their institutions. A multicenter, retrospective, observational study was conducted in Argentina, Brazil, Chile, Costa Rica, United Mexican States, and Peru. A standardized Cost Report Form collected data on 2 comparable patients per institution, 1 treated according to AMS guidelines and 1 without adherence. Data included hospitalization days, intensive care unit costs, antibiotic use, and total management expenses, converted to US dollars. A sensitivity analysis varied key cost parameters (hospitalization, intensive care unit stays, and antibiotics) by ±20% to assess cost stability. Adherence to AMS guidelines led to hospitalization net cost reductions across all institutions: Peru (57.8%), Argentina (49.6%), United Mexican States (38.9%), Brazil (2.6%), Chile (10.2%), and Costa Rica (7.6%). Daily cost savings per patient ranged from US dollars $3 (Brazil) to $570 (Peru). Sensitivity analysis confirmed stability under varying conditions, with adjusted savings from $810 to $9.999. This case-study highlights the economic benefits of AMS adherence, including reduced hospitalization and antibiotic costs. Findings provide insights supporting AMS program expansion across Latin America and the Caribbean healthcare systems to optimize resources.